Marksans Pharma has notified the stock exchanges of an upcoming board meeting scheduled for Tuesday, May 26, 2026, at Mumbai. The intimation has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will address key financial and corporate matters pertaining to the concluded fiscal year.

Key Agenda Items

The board meeting has been convened to transact the following businesses, as detailed in the regulatory filing:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's Internal Code on Prohibition of Insider Trading, the trading window for dealing in the company's shares has been closed for Designated Persons, including Directors, and their immediate relatives. The key details of the trading window restriction are as follows:

• Closure Date: April 01, 2026
• Re-opening Date: Forty-eight hours after the announcement of financial results, i.e., up to May 28, 2026 (both days inclusive)

Regulatory Compliance and Disclosure

As required under the Listing Regulations, the board meeting intimation is available on the company's official website at www.marksanspharma.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited. The filing was signed by Harshavardhan Panigrahi, Company Secretary, on May 12, 2026. The company is headquartered at the 11th Floor, "GRANDEUR", Oshiwara, Andheri (W), Mumbai – 400 053.

Marksans pharma Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory documentation with both BSE and NSE on April 09, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Details

The certificate was issued by Bigshare Services Private Limited, the company's appointed Registrar and Transfer Agent, on April 06, 2026. This documentation is required under the SEBI (Depositories and Participants) Regulations, 2018, specifically addressing the proper handling of securities dematerialization processes.

Certificate Confirmation

Bigshare Services confirmed that all securities received from depository participants for dematerialization up to March 31, 2026 were properly processed. The registrar verified that:

• Securities received for dematerialization were confirmed to depositories within regulatory timelines
• All securities are listed on stock exchanges where the company's earlier issued securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members as registered owners within 15 days of certificate receipt

Stock Exchange Communication

The company communicated with both major Indian stock exchanges regarding this compliance filing. BSE Limited received the documentation at its Corporate Relation Department, while NSE's Listing Department was notified of the regulatory submission.

Corporate Information

Marksans Pharma Limited operates from its registered office located at the 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri West, Mumbai. The company maintains regular communication with stakeholders through its dedicated investor relations channels and ensures timely compliance with all regulatory requirements.